NEUROENDOCRINE TUMORS

This early-phase trial tests a virus that attacks cancer cells (SVV-001) together with two immunotherapy drugs (nivolumab and ipilimumab) in adults with advanced neuroendocrine tumors or carcinomas that have worsened after standard treatment. The main goals are to find the safest…

This early-phase study tests a drug called tirapazamine, which becomes active in low-oxygen areas, combined with a procedure that blocks blood flow to liver tumors (embolization). The goal is to find the safest and most effective dose for people with liver cancer or liver-dominan…

This study looks at how well the drug cabozantinib works and how safe it is for adults with neuroendocrine tumors (NETs) that have continued to grow despite prior treatment. About 150 participants in Germany and Austria will be followed during their routine care. Researchers will…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and infuse th…

This study tests whether customizing the dose and schedule of a radioactive drug (177Lu-DOTATOC) based on each patient's tumor can be safer and more effective than the current one-size-fits-all approach. About 300 adults with advanced neuroendocrine tumors that are growing and ha…

This early-phase trial tests a new drug called ADCT-701 in adults with rare cancers of the digestive tract, pancreas, lungs, or adrenal glands. The main goal is to find the safest dose and see if the drug can shrink tumors. Participants receive the drug through an IV every 3 week…

This early-stage study tests an experimental pill called CID-078 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 220 adults with cancers like lung, breast…

This study tests a combination of two drugs (lenvatinib and pembrolizumab) in people with a rare, fast-growing type of neuroendocrine tumor called well-differentiated grade 3 (WD G3 NET). About 29 adults with advanced tumors that cannot be removed by surgery will receive the trea…

This early-phase study tests a new drug called NN3201, designed to find and attack cancer cells that have a specific protein called c-Kit. The trial includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others.…

This study looks at how well the drug surufatinib works for people with advanced neuroendocrine tumors (a type of cancer) in real-life medical settings. About 350 adults will take the drug by mouth, either alone or with other treatments, and be monitored for tumor shrinkage, side…

This study tests a different way of taking the drug cabozantinib to see if it causes fewer side effects while still controlling cancer growth. It includes adults with advanced kidney cancer or neuroendocrine tumors. The goal is to find a dose schedule that patients can tolerate b…

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be removed by surgery. The goal is to see if the drug can slow or stop tumor growth and to check its safety. About 130 adults will receive four do…

This phase 3 trial tests whether a targeted radiation therapy (177Lu-edotreotide) works better than a standard drug (everolimus) for people with certain lung or thymus neuroendocrine tumors. About 170 adults with advanced tumors that have receptors for a specific hormone will be …

This study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that cannot be removed by surgery and have grown after prior treatment with a type of radiation therapy (177Lu). The trial has two parts: first, finding the best dose, t…

This early-stage study tests a new drug called Sapu003 in people with advanced cancers that are sensitive to mTOR treatment, including certain breast cancers, kidney cancer, and liver cancer. The main goal is to find the safest dose and understand side effects. About 27 adults wi…

This study is for people with a type of intestinal cancer (neuroendocrine tumor) that has started growing again after initial treatment with Lutathera. It compares giving two more doses of Lutathera every two months versus simply watching and waiting. The goal is to see if the ex…

This study tests a new radioactive drug, Terbium-161 DOTATATE, in 20 adults with advanced neuroendocrine tumors that have spread and stopped responding to standard treatment. The drug delivers radiation directly to cancer cells while sparing healthy tissue, aiming to shrink or st…

This study is tracking 50 adults with neuroendocrine tumors (a rare type of cancer) to see how well a treatment called PRRT works. PRRT uses a radioactive drug to target and kill cancer cells. Researchers will monitor tumor shrinkage, survival time, and side effects to better und…

This early-phase study tests a new drug called BL-M14D1 in people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have spread and no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, a…

This study tests whether combining two drugs, Lutathera (a radioactive therapy) and Olaparib (a targeted pill), can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive the treatment over several months and be m…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The goal is to find a safe dose and see if t…

This study tests a new drug called CRN09682 in people with advanced neuroendocrine tumors and other solid tumors that have spread and are getting worse. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About 150 adults will take part…

This early-stage trial tests whether giving an oral drug (ASTX727) before standard Lutathera treatment can help the radiation reach more cancer cells in people with metastatic neuroendocrine tumors. About 27 adults will take ASTX727 for 5 days, then receive Lutathera on day 8. Th…

This study tests a combination of two treatments for people with neuroendocrine tumors (NETs) that have spread to the liver and cannot be removed by surgery. Participants receive chemotherapy pills (capecitabine and temozolomide) plus a one-time radiation treatment delivered dire…

This early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…

This study tests a new treatment called CHM-2101 for people with advanced gastrointestinal cancers (stomach, colon, or neuroendocrine tumors) that have stopped responding to standard therapies. The treatment uses a patient's own immune cells, modified to recognize and attack canc…

This study is testing whether a blood test for a protein called hPG80 can help detect neuroendocrine tumors (NETs) earlier in people with MEN1, a rare genetic condition that raises tumor risk. About 297 participants with MEN1 will give blood samples, which will be compared to sta…

This study is testing a special PET/CT scan that uses a form of tryptophan (a building block of protein) to see if it can make tumors stand out more clearly from healthy tissue. About 24 adults with certain brain, breast, neuroendocrine, or rectal cancers will get this scan. The …

This study tests a new radioactive tracer called 89Zr-TLX250 to see if it can better detect liver cancer, bile duct cancer, and certain neuroendocrine tumors on PET-CT scans. The tracer targets a protein (CAIX) found on these cancer cells. Researchers will compare the number and …

This study tests a new radioactive tracer called 68Ga-HA-DOTATATE for PET/CT scans in people with known or suspected neuroendocrine tumors. The goal is to see if it is safe and more accurate than older imaging methods. About 600 participants will be enrolled to measure how well t…

This study is testing a special PET scan (18F-DOPA) to see if it can better detect and measure several conditions, including congenital hyperinsulinism in children, neuroblastoma, neuroendocrine tumors, Parkinson's disease, Lewy body dementia, and brain tumors. About 800 children…

This study tests whether guarana, a natural plant extract, can improve fatigue in people with neuroendocrine tumors or gynecologic cancers. About 86 adults will take guarana or a placebo for up to 42 days, and researchers will measure changes in fatigue and quality of life. The g…

This study looks at how factors like age, sex, and tumor grade influence how well treatments work for a type of rare gut cancer called GEP-NENs. Researchers will follow 450 adults with well-differentiated tumors who are receiving standard therapies such as somatostatin analogs or…

This study is creating a large database of medical information and blood samples from 350 adults receiving metabolic radiotherapy for thyroid cancer, prostate cancer, or neuroendocrine tumors. The goal is to provide researchers with valuable data to better understand these treatm…

This study is testing whether an artificial intelligence tool can help match cancer patients to clinical trials they might be eligible for. Researchers will enroll up to 50,000 people with various types of cancer and use the AI to suggest trials. The goal is to see if this approa…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study is testing whether a special PET scan (using Detectnet) can help doctors plan Lutathera radiation therapy more safely for people with neuroendocrine cancer. Ten participants will get extra scans to see if the PET scan can predict how much radiation reaches tumors and h…

This study follows people with von Hippel-Lindau (VHL) disease who have growths in their pancreas. The goal is to learn how these tumors grow and change over time, and to test if a special type of scan (68-Gallium DOTATATE PET/CT) can find them better. Participants will have regu…

This study follows 300 adults with neuroendocrine tumors (including adrenocortical carcinoma) over their lifetime to understand how these rare cancers behave. Participants provide blood, urine, and tumor samples, and have yearly check-ups. The goal is to gather information and sa…

This study looks at whether follow-up care for people with rare tumors can be done just as well by a nurse remotely as by a doctor in person. About 88 adults recently diagnosed with a rare tumor will be randomly assigned to either in-person doctor visits or remote nurse check-ins…